MARY R. RENSEL
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
- Where
- INDEPENDENCE, OH
- NPI
- 1083640197
- Received
- $162,847 in 179 records, 2019 to 2025 ($154,010 general, $8,837 research)
- As principal investigator
- $528,517 of research payments to others in 47 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 37 | $13,006 |
| 2024 | General payment | 68 | $63,042 |
| 2024 | Research payment | 1 | $1,575 |
| 2023 | General payment | 17 | $24,946 |
| 2023 | Research payment | 1 | $2,100 |
| 2022 | General payment | 8 | $3,108 |
| 2021 | General payment | 14 | $18,204 |
| 2021 | Research payment | 1 | $3,500 |
| 2020 | General payment | 11 | $13,504 |
| 2020 | Research payment | 1 | $1,662 |
| 2019 | General payment | 20 | $18,197 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Genentech USA, Inc. | 37 | $37,035 | 2021–2025 |
| TG Therapeutics, Inc. | 35 | $29,783 | 2021–2025 |
| Biogen, Inc. | 35 | $27,228 | 2019–2025 |
| GENZYME CORPORATION | 15 | $19,685 | 2020–2025 |
| EMD Serono, Inc. | 17 | $18,093 | 2020–2025 |
| Novartis Pharmaceuticals Corporation | 26 | $14,750 | 2019–2025 |
| Horizon Therapeutics plc | 3 | $4,590 | 2021 |
| Celgene Corporation | 2 | $3,521 | 2024–2025 |
| E.R. Squibb & Sons, L.L.C. | 2 | $2,880 | 2022 |
| Merck Healthcare KGaA | 1 | $2,085 | 2024 |
| SANOFI-AVENTIS U.S. LLC | 2 | $1,769 | 2019 |
| Cycle Pharmaceuticals Inc | 1 | $1,300 | 2023 |
| Genentech, Inc. | 2 | $108 | 2024–2025 |
| Alexion Pharmaceuticals, Inc. | 1 | $16 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 28 | $85,084 |
| Consulting Fee | 14 | $47,002 |
| Research payment | 4 | $8,837 |
| Travel and Lodging | 29 | $7,419 |
| Food and Beverage | 98 | $4,480 |
| Grant | 1 | $3,500 |
| Compensation for serving as faculty or as a speaker for a medical education program | 1 | $3,500 |
| Honoraria | 1 | $3,000 |
| Education | 3 | $23 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-03 | TG Therapeutics, Inc. | $18 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-11-05 | GENZYME CORPORATION | $16 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-28 | Biogen, Inc. | $40 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-10-23 | TG Therapeutics, Inc. | $3,712 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-10-23 | TG Therapeutics, Inc. | $143 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-10-23 | TG Therapeutics, Inc. | $40 | Travel and Lodging | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-10-14 | EMD Serono, Inc. | $16 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-09-24 | TG Therapeutics, Inc. | $17 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-09-03 | Genentech USA, Inc. | $25 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2025 | |
| 2025-09-03 | Genentech USA, Inc. | $0 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2025 | |
| 2025-08-05 | Biogen, Inc. | $36 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-07-24 | GENZYME CORPORATION | $9 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-15 | TG Therapeutics, Inc. | $3,712 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-07-15 | TG Therapeutics, Inc. | $125 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-07-15 | TG Therapeutics, Inc. | $49 | Travel and Lodging | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-06-24 | EMD Serono, Inc. | $30 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-06-03 | TG Therapeutics, Inc. | $25 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-05-30 | EMD Serono, Inc. | $60 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-05-29 | Genentech, Inc. | $66 | Food and Beverage | In-kind items and services | Ocrevus Biological, Immunology | 2025 | |
| 2025-05-28 | Biogen, Inc. | $123 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-05-01 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-04-23 | Genentech USA, Inc. | $23 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2025 | |
| 2025-04-22 | TG Therapeutics, Inc. | $34 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-04-07 | Genentech USA, Inc. | $146 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2025 | |
| 2025-04-06 | Genentech USA, Inc. | $148 | Food and Beverage | In-kind items and services | Ocrevus Biological, Immunology | 2025 | |
| 2025-03-25 | EMD Serono, Inc. | $25 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-03-18 | GENZYME CORPORATION | $2,768 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-03-18 | GENZYME CORPORATION | $49 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-11 | Novartis Pharmaceuticals Corporation | $27 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-03-05 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-02-18 | Celgene Corporation | $21 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-02-17 | TG Therapeutics, Inc. | $1,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-02-04 | TG Therapeutics, Inc. | $30 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-01-29 | TG Therapeutics, Inc. | $15 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-01-28 | EMD Serono, Inc. | $25 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-01-09 | Genentech USA, Inc. | $1 | Travel and Lodging | Cash or cash equivalent | Ocrevus Biological, Immunology | 2025 | |
| 2025-01-07 | TG Therapeutics, Inc. | $25 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2024-12-21 | Novartis Pharmaceuticals Corporation | $19 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-12-17 | TG Therapeutics, Inc. | $3,712 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2024 | |
| 2024-12-17 | TG Therapeutics, Inc. | $143 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2024 | |
| 2024-12-17 | TG Therapeutics, Inc. | $53 | Travel and Lodging | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2024 | |
| 2024-12-12 | Genentech USA, Inc. | $5,520 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-12 | Genentech USA, Inc. | $5,520 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Ocrevus Biological, Immunology | 2024 | |
| 2024-12-12 | Merck Healthcare KGaA | $2,085 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-03 | GENZYME CORPORATION | $33 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-29 | Genentech USA, Inc. | $26 | Travel and Lodging | Cash or cash equivalent | Ocrevus Biological, Immunology | 2024 | |
| 2024-11-21 | Genentech USA, Inc. | $3,450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Ocrevus Biological, Immunology | 2024 | |
| 2024-11-20 | Genentech USA, Inc. | $21 | Food and Beverage | In-kind items and services | Ocrevus Biological, Immunology | 2024 | |
| 2024-11-20 | Genentech USA, Inc. | $2 | Food and Beverage | In-kind items and services | Ocrevus Biological, Immunology | 2024 | |
| 2024-11-14 | TG Therapeutics, Inc. | $1,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2024 | |
| 2024-11-13 | TG Therapeutics, Inc. | $4,387 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2024 | |
| 2024-11-13 | TG Therapeutics, Inc. | $287 | Travel and Lodging | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2024 | |
| 2024-11-13 | TG Therapeutics, Inc. | $243 | Travel and Lodging | In-kind items and services | BRIUMVI Drug, Immunology | 2024 | |
| 2024-11-13 | TG Therapeutics, Inc. | $124 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2024 | |
| 2024-11-13 | TG Therapeutics, Inc. | $8 | Food and Beverage | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2024 | |
| 2024-11-08 | Genentech USA, Inc. | $1,100 | Travel and Lodging | In-kind items and services | Ocrevus Biological, Immunology | 2024 | |
| 2024-11-08 | Genentech USA, Inc. | $27 | Food and Beverage | In-kind items and services | Ocrevus Biological, Immunology | 2024 | |
| 2024-11-07 | Genentech USA, Inc. | $1,095 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-11-07 | Genentech USA, Inc. | $124 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-07 | Genentech USA, Inc. | $89 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-11-07 | Genentech USA, Inc. | $89 | Travel and Lodging | In-kind items and services | Ocrevus Biological, Immunology | 2024 | |
| 2024-10-23 | Genentech USA, Inc. | $110 | Travel and Lodging | In-kind items and services | Ocrevus Biological, Immunology | 2024 | |
| 2024-10-18 | Genentech USA, Inc. | $20 | Travel and Lodging | In-kind items and services | Ocrevus Biological, Immunology | 2024 | |
| 2024-10-18 | Genentech USA, Inc. | $20 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-10-18 | Genentech USA, Inc. | $19 | Food and Beverage | In-kind items and services | Ocrevus Biological, Immunology | 2024 | |
| 2024-10-17 | Genentech USA, Inc. | $13 | Food and Beverage | In-kind items and services | Ocrevus Biological, Immunology | 2024 | |
| 2024-10-10 | Novartis Pharmaceuticals Corporation | $44 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-10-09 | Novartis Pharmaceuticals Corporation | $112 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-10-04 | Genentech USA, Inc. | $80 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-10-02 | Novartis Pharmaceuticals Corporation | $29 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-09-25 | TG Therapeutics, Inc. | $3,712 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2024 | |
| 2024-09-25 | TG Therapeutics, Inc. | $48 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2024 | |
| 2024-09-25 | TG Therapeutics, Inc. | $40 | Travel and Lodging | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2024 | |
| 2024-08-28 | TG Therapeutics, Inc. | $11 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2024 | |
| 2024-08-28 | TG Therapeutics, Inc. | $4 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2024 | |
| 2024-08-21 | Biogen, Inc. | $24 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2024 | |
| 2024-08-08 | Genentech USA, Inc. | $5,520 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-08-08 | Genentech USA, Inc. | $148 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-08 | Genentech USA, Inc. | $131 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-08 | Genentech USA, Inc. | $93 | Travel and Lodging | Cash or cash equivalent | 2024 | ||
| 2024-08-06 | Biogen, Inc. | $17 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2024 | |
| 2024-07-30 | TG Therapeutics, Inc. | $3,712 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2024 | |
| 2024-07-30 | TG Therapeutics, Inc. | $125 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2024 | |
| 2024-07-25 | Genentech USA, Inc. | $5,520 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-07-25 | Genentech USA, Inc. | $1,410 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-07-25 | Genentech USA, Inc. | $353 | Travel and Lodging | Cash or cash equivalent | 2024 | ||
| 2024-07-25 | Genentech USA, Inc. | $97 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-07-25 | Genentech USA, Inc. | $35 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-06-25 | Novartis Pharmaceuticals Corporation | $7 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-06-19 | EMD Serono, Inc. | $13 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-06-14 | TG Therapeutics, Inc. | $29 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2024 | |
| 2024-06-05 | Novartis Pharmaceuticals Corporation | $13 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-06-03 | TG Therapeutics, Inc. | $465 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2024 | |
| 2024-05-30 | Biogen, Inc. | $130 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2024 | |
| 2024-05-30 | Genentech, Inc. | $42 | Food and Beverage | In-kind items and services | Ocrevus Biological, Immunology | 2024 | |
| 2024-05-24 | Celgene Corporation | $3,500 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | 2024 | ||
| 2024-05-11 | TG Therapeutics, Inc. | $45 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2024 | |
| 2024-04-30 | Genentech USA, Inc. | $32 | Food and Beverage | In-kind items and services | Ocrevus Biological, Immunology | 2024 | |
| 2024-04-29 | EMD Serono, Inc. | $4,170 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-04-10 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-04-03 | Novartis Pharmaceuticals Corporation | $6 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-03-05 | TG Therapeutics, Inc. | $38 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2024 | |
| 2024-02-27 | Biogen, Inc. | $1,575 | Research payment | Cash or cash equivalent | TECFIDERA Drug, Neurology | Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00 | 2024 |
| 2024-02-15 | GENZYME CORPORATION | $3,500 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-02-13 | Biogen, Inc. | $36 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2024 | |
| 2024-02-13 | Biogen, Inc. | $15 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2024 | |
| 2023-12-05 | Biogen, Inc. | $40 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2023 | |
| 2023-11-15 | EMD Serono, Inc. | $5,386 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-11-15 | Genentech USA, Inc. | $3,450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-11-15 | Genentech USA, Inc. | $120 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-11-01 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2023 | |
| 2023-10-23 | GENZYME CORPORATION | $321 | Travel and Lodging | Cash or cash equivalent | 2023 | ||
| 2023-10-23 | GENZYME CORPORATION | $49 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-10-23 | GENZYME CORPORATION | $44 | Travel and Lodging | Cash or cash equivalent | 2023 | ||
| 2023-10-16 | GENZYME CORPORATION | $8,418 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-07-07 | EMD Serono, Inc. | $2,640 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-06-02 | Biogen, Inc. | $55 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-05-16 | Biogen, Inc. | $29 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2023 | |
| 2023-04-19 | GENZYME CORPORATION | $2,928 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-04-19 | GENZYME CORPORATION | $108 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-04-19 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2023 | |
| 2023-01-20 | Cycle Pharmaceuticals Inc | $1,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NITYR Drug, Gastrointestinal | 2023 | |
| 2023-01-19 | Biogen, Inc. | $2,100 | Research payment | Cash or cash equivalent | TECFIDERA Drug, Neurology | Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00 | 2023 |
| 2023-01-18 | Novartis Pharmaceuticals Corporation | $19 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2023 | |
| 2022-12-07 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-11-29 | Biogen, Inc. | $37 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2022 | |
| 2022-10-26 | E.R. Squibb & Sons, L.L.C. | $1,440 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-08-15 | E.R. Squibb & Sons, L.L.C. | $1,440 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-07-01 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-06-08 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-06-02 | GENZYME CORPORATION | $28 | Food and Beverage | In-kind items and services | AUBAGIO Drug, Neurology | 2022 | |
| 2022-06-01 | GENZYME CORPORATION | $110 | Food and Beverage | In-kind items and services | AUBAGIO Drug, Neurology | 2022 | |
| 2021-11-17 | Biogen, Inc. | $568 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-10-29 | Horizon Therapeutics plc | $1,034 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | UPLIZNA Drug, UPLIZNA | 2021 | |
| 2021-09-23 | TG Therapeutics, Inc. | $1,940 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-09-09 | Novartis Pharmaceuticals Corporation | $2,128 | Consulting Fee | Cash or cash equivalent | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-08-26 | Biogen, Inc. | $30 | Food and Beverage | In-kind items and services | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-08-19 | Biogen, Inc. | $17 | Food and Beverage | In-kind items and services | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-08-05 | Horizon Therapeutics plc | $3,000 | Honoraria | Cash or cash equivalent | UPLIZNA Drug, UPLIZNA | 2021 | |
| 2021-08-04 | Novartis Pharmaceuticals Corporation | $19 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-07-14 | Alexion Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | Soliris Drug, Immunology | 2021 | |
| 2021-06-24 | Novartis Pharmaceuticals Corporation | $798 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MAYZENT Drug, NEUROSCIENCE | 2021 | |
| 2021-06-16 | Genentech USA, Inc. | $2,445 | Consulting Fee | Cash or cash equivalent | Enspryng Biological, Immunology | 2021 | |
| 2021-05-13 | Biogen, Inc. | $3,500 | Research payment | Cash or cash equivalent | TECFIDERA Drug, NEUROLOGY | Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) | 2021 |
| 2021-03-31 | Horizon Therapeutics plc | $555 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | UPLIZNA Drug, UPLIZNA | 2021 | |
| 2021-02-18 | Biogen, Inc. | $2,825 | Consulting Fee | Cash or cash equivalent | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-02-05 | Biogen, Inc. | $2,825 | Consulting Fee | Cash or cash equivalent | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2020-12-03 | GENZYME CORPORATION | $1,298 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AUBAGIO Drug, Neurology | 2020 | |
| 2020-09-18 | Novartis Pharmaceuticals Corporation | $6,384 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-03-23 | EMD Serono, Inc. | $4,620 | Consulting Fee | Cash or cash equivalent | Mavenclad Drug, Neurology | 2020 | |
| 2020-03-23 | EMD Serono, Inc. | $43 | Food and Beverage | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-03-19 | Biogen, Inc. | $1,662 | Research payment | Cash or cash equivalent | TECFIDERA Drug, NEUROLOGY | Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) | 2020 |
| 2020-02-27 | Biogen, Inc. | $96 | Food and Beverage | In-kind items and services | TYSABRI Biological, NEUROLOGY | 2020 | |
| 2020-02-08 | EMD Serono, Inc. | $662 | Travel and Lodging | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-02-08 | EMD Serono, Inc. | $216 | Travel and Lodging | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-02-08 | EMD Serono, Inc. | $69 | Travel and Lodging | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-02-08 | EMD Serono, Inc. | $50 | Food and Beverage | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-02-08 | EMD Serono, Inc. | $34 | Food and Beverage | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-02-08 | EMD Serono, Inc. | $29 | Food and Beverage | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2019-11-02 | SANOFI-AVENTIS U.S. LLC | $1,713 | Consulting Fee | Cash or cash equivalent | NO PRODUCT DISCUSSED Drug | 2019 | |
| 2019-11-02 | SANOFI-AVENTIS U.S. LLC | $56 | Travel and Lodging | Cash or cash equivalent | NO PRODUCT DISCUSSED Drug | 2019 | |
| 2019-09-25 | Biogen, Inc. | $3,675 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-09-25 | Biogen, Inc. | $49 | Food and Beverage | Cash or cash equivalent | 2019 | ||
| 2019-08-22 | Biogen, Inc. | $12 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-08-22 | Biogen, Inc. | $7 | Food and Beverage | In-kind items and services | TECFIDERA Drug, NEUROLOGY | 2019 | |
| 2019-08-07 | Biogen, Inc. | $9 | Education | In-kind items and services | TYSABRI Biological, NEUROLOGY | 2019 | |
| 2019-08-01 | Biogen, Inc. | $3,675 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-08-01 | Biogen, Inc. | $125 | Food and Beverage | Cash or cash equivalent | 2019 | ||
| 2019-07-23 | Biogen, Inc. | $3,675 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-07-23 | Biogen, Inc. | $50 | Food and Beverage | Cash or cash equivalent | 2019 | ||
| 2019-07-17 | Biogen, Inc. | $2 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-07-10 | Biogen, Inc. | $9 | Education | In-kind items and services | TYSABRI Biological, NEUROLOGY | 2019 | |
| 2019-07-10 | Biogen, Inc. | $4 | Education | In-kind items and services | TECFIDERA Drug, NEUROLOGY | 2019 | |
| 2019-05-08 | Biogen, Inc. | $142 | Food and Beverage | In-kind items and services | TECFIDERA Drug, NEUROLOGY | 2019 | |
| 2019-02-21 | Novartis Pharmaceuticals Corporation | $4,256 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-02-21 | Novartis Pharmaceuticals Corporation | $561 | Travel and Lodging | In-kind items and services | 2019 | ||
| 2019-02-21 | Novartis Pharmaceuticals Corporation | $114 | Travel and Lodging | In-kind items and services | 2019 | ||
| 2019-02-21 | Novartis Pharmaceuticals Corporation | $37 | Food and Beverage | Cash or cash equivalent | 2019 | ||
| 2019-02-21 | Novartis Pharmaceuticals Corporation | $20 | Travel and Lodging | Cash or cash equivalent | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-01 | Hoffmann-La Roche Limited | Cleveland Clinic Hospital | $6,215 | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2025 |
| 2025-10-15 | Genentech, Inc. | Cleveland Clinic Hospital | $1,912 | Paediatric PK study in multiple sclerosis patients | 2025 |
| 2025-09-10 | Hoffmann-La Roche Limited | Cleveland Clinic Hospital | $197 | OPERETTA II Ocrelizumab Pediatric Phase III study | 2025 |
| 2025-09-05 | Hoffmann-La Roche Limited | Cleveland Clinic Hospital | $11,978 | OPERETTA II Ocrelizumab Pediatric Phase III study | 2025 |
| 2025-08-20 | Genentech, Inc. | Cleveland Clinic Hospital | $472 | Paediatric PK study in multiple sclerosis patients | 2025 |
| 2025-04-28 | Genentech, Inc. | Cleveland Clinic Hospital | $4,309 | Paediatric PK study in multiple sclerosis patients | 2025 |
| 2025-02-26 | Hoffmann-La Roche Limited | Cleveland Clinic Hospital | $2,121 | OPERETTA II Ocrelizumab Pediatric Phase III study | 2025 |
| 2025-01-22 | Genentech, Inc. | Cleveland Clinic Hospital | $5,281 | Paediatric PK study in multiple sclerosis patients | 2025 |
| 2024-12-06 | Genentech, Inc. | Cleveland Clinic Hospital | $1,964 | Paediatric PK study in multiple sclerosis patients | 2024 |
| 2024-11-06 | Hoffmann-La Roche Limited | Cleveland Clinic Hospital | $10,627 | OPERETTA II Ocrelizumab Pediatric Phase III study | 2024 |
| 2024-11-04 | Genentech, Inc. | Cleveland Clinic Hospital | $8,352 | Paediatric PK study in multiple sclerosis patients | 2024 |
| 2024-10-23 | Genentech, Inc. | Cleveland Clinic Hospital | $338 | Paediatric PK study in multiple sclerosis patients | 2024 |
| 2024-10-21 | Genentech, Inc. | Cleveland Clinic Hospital | $2,328 | Paediatric PK study in multiple sclerosis patients | 2024 |
| 2024-08-07 | Hoffmann-La Roche Limited | Cleveland Clinic Hospital | $10,850 | OPERETTA II Ocrelizumab Pediatric Phase III study | 2024 |
| 2024-07-22 | Genentech, Inc. | Cleveland Clinic Hospital | $1,534 | Paediatric PK study in multiple sclerosis patients | 2024 |
| 2024-07-22 | Genentech, Inc. | Cleveland Clinic Hospital | $6,233 | Paediatric PK study in multiple sclerosis patients | 2024 |
| 2024-06-26 | Genentech, Inc. | Cleveland Clinic Hospital | $28,744 | Paediatric PK study in multiple sclerosis patients | 2024 |
| 2024-06-12 | Hoffmann-La Roche Limited | Cleveland Clinic Hospital | $858 | OPERETTA II Ocrelizumab Pediatric Phase III study | 2024 |
| 2024-04-26 | Hoffmann-La Roche Limited | Cleveland Clinic Hospital | $3,403 | OPERETTA II Ocrelizumab Pediatric Phase III study | 2024 |
| 2024-04-18 | Genentech, Inc. | Cleveland Clinic Hospital | $5,304 | Paediatric PK study in multiple sclerosis patients | 2024 |
| 2024-03-04 | Genentech, Inc. | Cleveland Clinic Hospital | $1,534 | Paediatric PK study in multiple sclerosis patients | 2024 |
| 2024-02-02 | Hoffmann-La Roche Limited | Cleveland Clinic Hospital | $10,781 | OPERETTA II Ocrelizumab Pediatric Phase III study | 2024 |
| 2023-11-06 | Genentech, Inc. | Cleveland Clinic Hospital | $5,689 | Paediatric PK study in multiple sclerosis patients | 2023 |
| 2023-10-25 | Hoffmann-La Roche Limited | Cleveland Clinic Hospital | $14,545 | OPERETTA II Ocrelizumab Pediatric Phase III study | 2023 |
| 2023-10-04 | Hoffmann-La Roche Limited | Cleveland Clinic Hospital | $3,500 | OPERETTA II Ocrelizumab Pediatric Phase III study | 2023 |
| 2023-10-04 | Hoffmann-La Roche Limited | Cleveland Clinic Hospital | $2,800 | OPERETTA II Ocrelizumab Pediatric Phase III study | 2023 |
| 2023-10-04 | Hoffmann-La Roche Limited | Cleveland Clinic Hospital | $15,171 | OPERETTA II Ocrelizumab Pediatric Phase III study | 2023 |
| 2023-09-08 | Hoffmann-La Roche Limited | Cleveland Clinic Hospital | $16,525 | OPERETTA II Ocrelizumab Pediatric Phase III study | 2023 |
| 2023-07-28 | Genentech, Inc. | Cleveland Clinic Hospital | $1,534 | Paediatric PK study in multiple sclerosis patients | 2023 |
| 2023-07-13 | Genentech, Inc. | Cleveland Clinic Hospital | $5,620 | Paediatric PK study in multiple sclerosis patients | 2023 |
| 2023-01-23 | Genentech, Inc. | Cleveland Clinic Hospital | $5,689 | Paediatric PK study in multiple sclerosis patients | 2023 |
| 2022-10-28 | Genentech, Inc. | Cleveland Clinic Hospital | $1,354 | PAEDIATRIC PK STUDY IN MULTIPLE SCLEROSIS PATIENTS | 2022 |
| 2022-10-28 | Genentech, Inc. | Cleveland Clinic Hospital | $1,602 | PAEDIATRIC PK STUDY IN MULTIPLE SCLEROSIS PATIENTS | 2022 |
| 2022-07-27 | Genentech, Inc. | Cleveland Clinic Hospital | $7,155 | PAEDIATRIC PK STUDY IN MULTIPLE SCLEROSIS PATIENTS | 2022 |
| 2022-04-25 | Genentech, Inc. | Cleveland Clinic Hospital | $3,829 | PAEDIATRIC PK STUDY IN MULTIPLE SCLEROSIS PATIENTS | 2022 |
| 2022-04-11 | Genentech, Inc. | Cleveland Clinic Hospital | $1,015 | PAEDIATRIC PK STUDY IN MULTIPLE SCLEROSIS PATIENTS | 2022 |
| 2022-01-24 | Genentech, Inc. | Cleveland Clinic Hospital | $6,752 | PAEDIATRIC PK STUDY IN MULTIPLE SCLEROSIS PATIENTS | 2022 |
| 2022-01-24 | Genentech, Inc. | Cleveland Clinic Hospital | $338 | PAEDIATRIC PK STUDY IN MULTIPLE SCLEROSIS PATIENTS | 2022 |
| 2021-10-20 | Genentech, Inc. | Cleveland Clinic Hospital | $2,343 | PAEDIATRIC PK STUDY IN MULTIPLE SCLEROSIS PATIENTS | 2021 |
| 2021-07-26 | Genentech, Inc. | Cleveland Clinic Hospital | $6,513 | PAEDIATRIC PK STUDY IN MULTIPLE SCLEROSIS PATIENTS | 2021 |
| 2021-05-25 | AstraZeneca Pharmaceuticals LP | Cleveland Clinic Hospital | $101,265 | A Double masked Placebo controlled Study with Open label Period to Evaluate the Efficacy and Safety of MEDI551 in Adult | 2021 |
| 2021-04-14 | Genentech, Inc. | Cleveland Clinic Hospital | $4,331 | PAEDIATRIC PK STUDY IN MULTIPLE SCLEROSIS PATIENTS | 2021 |
| 2021-01-15 | Genentech, Inc. | Cleveland Clinic Hospital | $12,844 | PAEDIATRIC PK STUDY IN MULTIPLE SCLEROSIS PATIENTS | 2021 |
| 2020-04-28 | Genentech, Inc. | Cleveland Clinic Hospital | $19,038 | PAEDIATRIC PK STUDY IN MULTIPLE SCLEROSIS PATIENTS | 2020 |
| 2020-01-14 | AstraZeneca Pharmaceuticals LP | Cleveland Clinic Hospital | $77,904 | A Double masked Placebo controlled Study with Open label Period to Evaluate the Efficacy and Safety of MEDI551 in Adult | 2020 |
| 2019-10-08 | AstraZeneca Pharmaceuticals LP | CLEVELAND CLINIC HOSPITAL | $82,799 | A Double masked Placebo controlled Study with Open label Period to Evaluate the Efficacy and Safety of MEDI551 in Adult | 2019 |
| 2019-08-26 | Genentech, Inc. | CLEVELAND CLINIC HOSPITAL | $3,010 | PAEDIATRIC PK STUDY IN MULTIPLE SCLEROSIS PATIENTS | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Independence, OH, county Cuyahoga County, OH, state Ohio; placed by its city name.
| Measure | Place (city or town) Independence, OH | County Cuyahoga County, OH | State Ohio |
|---|---|---|---|
| Population B01003 | 7,534 | 1,245,873 | 11,810,293 |
| Population, 2020 census P1 | 7,584 | 1,264,817 | 11,799,448 |
| Median age B01002 | 48.4 | 40.4 | 39.7 |
| Under 18 B01001 | 19.2% | 20.5% | 22.0% |
| 65 and over B01001 | 25.5% | 19.5% | 18.3% |
| Households B11001 | 3,121 | 554,551 | 4,863,191 |
| Foreign born B05002 | 3.1% | 7.7% | 5.2% |
| Median household income B19013 | $115,733 | $64,468 | $71,389 |
| Median family income B19113 | $126,413 | $89,252 | $92,749 |
| Per capita income B19301 | $58,711 | $42,747 | $40,552 |
| Poverty rate B17001 | 2.4% | 16.1% | 13.3% |
| Unemployment rate B23025 | 1.5% | 6.6% | 4.8% |
| Civilian labor force B23025 | 4,068 | 650,577 | 5,994,779 |
| Mean commute (minutes) B08013 | 22.6 | 23.3 | 23.4 |
| Bachelor's degree or higher B15003 | 47.4% | 36.5% | 31.5% |
| Housing units B25001 | 3,217 | 615,331 | 5,292,391 |
| Owner-occupied B25003 | 90.4% | 59.4% | 67.2% |
| Renters B25003 | 9.6% | 40.6% | 32.8% |
| Median home value B25077 | $309,900 | $195,400 | $214,800 |
| Median gross rent B25064 | $1,383 | $1,060 | $1,034 |
| White, not Hispanic B03002 | 92.4% | 56.5% | 75.8% |
| Black B03002 | 1.8% | 28.5% | 12.0% |
| Hispanic or Latino B03002 | 1.3% | 7.0% | 4.8% |
| Asian B03002 | 1.4% | 3.3% | 2.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Independence, OH.
Comments